Technical standards and guidelines: Prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements: Erratum
In the article that appeared on page 669 of volume 11, issue 9, the authors' disclosures were omitted mistakenly. The authors' disclosures should have appeared as follows: Glenn E. Palomaki reports that he has no personal conflicts of interest to disclose, but his employer has received project grants from Beckman Coulter, PerkinElmer and DSL. Jo Ellen S. Lee reports that she is a consultant for Genzyme Genetics. Jacob A. Canick reports that, with others, he hold patents on the use of unconjugated estriol in prenatal screening for Down syndrome and is a paid consultant to Beckman Coulter Inc. Geraldine A. McDowell declares no conflicts of interest. Alan E. Donnenfeld is an employee of Genzyme Genetics.
This error has been noted in the online version of the article, which is available at www.geneticsinmedicine.com.
REFERENCE
Palomaki GE, Lee JES, Canick JA, McDowell GA, Donnenfeld AE, for the ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines: Prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements. Genet Med 2009; 11: 669–681.
Additional information
The online version of the original article can be found at 10.1097/GIM.0b013e3181ad5246
Rights and permissions
About this article
Cite this article
Erratum. Genet Med 11, 873 (2009). https://doi.org/10.1097/GIM.0b013e3181c949c8
Issue date:
DOI: https://doi.org/10.1097/GIM.0b013e3181c949c8